Pancreatic Cancer Research

ResearcherDalian Medical UniversityActive in the last 2 years

Mengyuan Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1788-8267; OpenAlex author ID A5101712943. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 3

  1. The TRIB1-PPARγ Axis Regulates Cholesterol Metabolism in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1111/nyas.70224↗
  2. RIOK3 promotes mTORC1 activation by facilitating SLC7A2-mediated arginine uptake in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/aging.204528↗
  3. RIOK3 promotes pancreatic ductal adenocarcinoma cell invasion and metastasis by stabilizing FAK. Co-author DOI 10.1016/j.heliyon.2022.e10116↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhen Ning · 3 shared papers, 2022–2026 · strength 0.66
  2. Henan Qin · 3 shared papers, 2022–2026 · strength 0.66
  3. Aman Wang · 2 shared papers, 2022–2023 · strength 0.36
  4. A M Wang · 1 shared paper, 2026 · strength 0.30
  5. Rui Sun · 1 shared paper, 2026 · strength 0.30
  6. Jiwei Liu · 1 shared paper, 2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.